HIV in Vietnam is a treatable chronic infection when it is diagnosed and antiretroviral therapy is taken consistently. HIV damages the immune system, particularly CD4 cells, but effective treatment can protect health and prevent sexual transmission when viral suppression is sustained. Testing is the only way to know HIV status.
For residents, travellers and expatriates, the practical questions are where to obtain a reliable test, what to do after a recent exposure and how to maintain treatment while living in Vietnam. A possible exposure within 72 hours needs urgent assessment for post-exposure prophylaxis, or PEP; routine symptoms and appearance cannot confirm or exclude infection.
HIV prevalence in Vietnam
Vietnam has made substantial progress against HIV, but infection has not disappeared. WHO reported in 2025 that annual new infections had fallen by nearly 60%, from about 14,000 in 2010 to fewer than 6,300 in 2024. WHO also described approximately 250,000 people living with HIV in Vietnam in 2024. These are national estimates, not a way to calculate one person’s risk.
HIV is concentrated more heavily in some key populations and networks than in the general population. Risk depends on a specific exposure, use of prevention and whether a partner with HIV has sustained viral suppression. National prevalence should not be used to assume that a Vietnamese partner has HIV or that an expatriate is protected from it. Use testing and exposure-based prevention rather than nationality or appearance.
Vietnam is close to the global 95-95-95 treatment targets and provides testing, ART, PrEP and community-based services, although access and available formulations vary by location. People seeking confidential care can start with a recognized HIV or sexual-health service. Our guide to emergency numbers in Vietnam explains how to reach urgent help, while what to do if you get sick in Vietnam covers practical routes to assessment.
A possible exposure within 72 hours needs prompt action
Post-exposure prophylaxis, or PEP, is an emergency course of HIV medicines for certain possible exposures. It should begin as soon as possible, ideally within 24 hours and no later than 72 hours after the exposure. Do not wait for symptoms, a partner's test result or a routine appointment if PEP may be needed.
Examples requiring assessment include a condom breaking during a potentially significant sexual exposure, sharing injection equipment or a needlestick involving potentially infectious blood. The clinician considers the fluid, route, timing and source information; ordinary social contact does not require PEP.
PEP is usually taken for 28 days. Baseline testing is important, but the first dose should not be delayed while appropriate laboratory results are pending. If more than 72 hours have passed, still seek advice about testing, other infection risks and future prevention. Do not start borrowed HIV medicines without an appropriate regimen and follow-up plan.
HIV and AIDS are different terms
HIV is the virus and the infection it causes. AIDS is the most advanced stage, associated with substantial immune damage and particular opportunistic illnesses. Receiving an HIV diagnosis does not mean a person already has AIDS or will inevitably develop it.
The early stage may involve rapid viral multiplication. A chronic stage can then last for years with few or no symptoms, even while untreated infection affects the immune system. Antiretroviral therapy, usually called ART, can prevent progression and allow immune recovery.
Two common measurements answer different questions. Viral load measures the amount of HIV in blood and helps assess treatment response. The CD4 count helps assess immune function and the need for prevention of certain opportunistic infections. Feeling well cannot replace these measurements.
How HIV is transmitted
Transmission involves particular body fluids, including blood, semen, pre-seminal fluid, rectal fluid, vaginal fluid and breast milk. These must reach susceptible tissue, a mucous membrane or the bloodstream. The main routes are anal or vaginal sex without effective prevention, shared injection equipment and transmission during pregnancy, birth or breastfeeding.
Risk varies with the type of exposure and the source person's viral load. Anal sex generally carries greater risk than vaginal sex when HIV is present without effective treatment. Oral sex has little to no HIV risk, although other sexually transmitted infections can spread that way.
HIV does not spread through hugging, shaking hands, sharing meals, toilets, swimming pools or mosquito bites. Saliva alone does not transmit HIV. People living with HIV do not need separate crockery or exclusion from ordinary family, school or workplace contact.
Symptoms cannot confirm or exclude infection
Some people develop a flu-like illness around two to four weeks after acquiring HIV, with fever, sore throat, rash, swollen glands or fatigue. Others have no noticeable symptoms. These symptoms overlap with many common infections and are not a diagnostic checklist.
Later untreated infection may cause persistent fever, weight loss, prolonged diarrhoea or recurrent infections. The absence of these problems does not establish a negative HIV status. Equally, a rash or mouth ulcer does not by itself make HIV likely.
If a recent exposure is followed by a compatible illness, tell the clinician about both timing and symptoms. An antibody test alone may be negative in early infection, so a different test or repeat testing may be appropriate. Do not wait for a characteristic rash before seeking PEP assessment.
Understanding the main HIV tests
Antibody tests look for the body's response to HIV. Many rapid tests and self-tests use this approach. Antigen/antibody tests can detect both antibodies and a viral protein called p24, which can appear earlier. Nucleic acid tests, or NATs, detect viral genetic material.
The specimen and method matter. A laboratory antigen/antibody test using blood from a vein is not the same as a rapid finger-prick test or an oral-fluid self-test. The label fourth generation does not remove the need to know which specimen and platform were used.
A reactive screening or self-test result requires follow-up testing through the national diagnostic algorithm. It should lead to prompt care, not to a diagnosis based on one home strip. An invalid self-test has not provided a usable result and needs repeating according to instructions or replacement with facility testing.
The window period and repeat testing
The window period is the interval after exposure before a test can usually detect infection. CDC describes typical ranges of 23–90 days for antibody tests, 18–90 days for rapid finger-prick antigen/antibody tests, 18–45 days for laboratory antigen/antibody tests using venous blood, and 10–33 days for NATs.
These ranges are not a guarantee that every negative test at the earliest day is conclusive. A negative result soon after exposure may need repeating after the relevant window period. Any new exposure creates a new timing question.
PEP or PrEP use can affect the testing plan because antiretroviral medicines may influence early detection. Follow the clinician's schedule rather than applying an untreated-exposure timetable to yourself. Testing immediately after an exposure can establish a baseline, but cannot rule out infection from something that happened only hours earlier.
Starting treatment after diagnosis
ART is recommended for people with HIV and should be started promptly after diagnosis, with clinical assessment. Treatment uses a combination of medicines that block viral replication at different points. Many people take a convenient daily combination tablet, although the appropriate regimen varies.
The choice depends on factors such as resistance, kidney function, hepatitis B, pregnancy and other medicines. Certain serious opportunistic infections can affect the timing of ART, so advanced illness needs specialist management rather than an automatic unsupervised start.
ART controls HIV but does not remove all virus reservoirs from the body. There is no generally available cure, and supplements or herbal products do not replace treatment. An undetectable viral load is a treatment success, not a reason to stop medicines.
What undetectable equals untransmittable means
People who take ART and achieve and maintain viral suppression do not transmit HIV through sex. This is summarized as U=U, or K=K in Vietnamese. The evidence supporting prevention of sexual transmission uses sustained suppression below 200 copies per millilitre; laboratory detection limits may be lower.
This is different from assuming that anyone who has recently started treatment is already suppressed. Viral load testing confirms the response, and continued treatment maintains it. If treatment is interrupted or the viral load becomes detectable above the suppression threshold, obtain advice about restoring suppression and prevention meanwhile.
U=U refers specifically to sexual transmission. It should not be converted into a claim of zero risk through breastfeeding or shared injection equipment. Condoms may still be useful for preventing other sexually transmitted infections and pregnancy, even when HIV sexual transmission is prevented by sustained suppression.
Adherence, side effects and resistance
Taking medicines as prescribed helps keep viral replication suppressed. Repeated interruptions or an ineffective regimen can allow resistance to develop, limiting the activity of some medicines. A missed dose is a reason to follow the product's advice or contact the treatment team, not to panic or double doses automatically.
Side effects depend on the regimen. Nausea, sleep changes or other symptoms may improve or may require an adjustment. Tell the clinician about persistent problems rather than stopping ART alone. Severe rash, breathing difficulty or other major reactions need urgent assessment.
Drug interactions can involve prescription medicines, antacids, mineral supplements and herbal products. For example, some HIV medicines require attention to calcium or iron timing. Instructions are drug-specific; a pharmacist should check the actual combination rather than applying a single spacing rule to every regimen.
Follow-up protects more than the viral load
Follow-up assesses viral suppression, immune recovery and treatment tolerability. Depending on the regimen and health history, monitoring may include kidney or liver function, metabolic health and other infection tests. A single small viral-load fluctuation does not automatically mean treatment has failed; its interpretation may require repeat testing.
Tuberculosis is especially important because HIV increases the likelihood that latent TB will progress to active disease. Persistent cough, fever, night sweats or unexplained weight loss should be assessed. TB testing and preventive treatment may be appropriate after active disease is excluded.
Vaccination, screening for hepatitis and sexually transmitted infections, and prevention of opportunistic illness are also part of care. People with low CD4 counts may need additional preventive medicines. These are tailored to immune status and exposures, not prescribed identically to everyone with HIV.
PrEP prevents infection before exposure
Pre-exposure prophylaxis, or PrEP, is for people without HIV who may be exposed through sex or injection drug use. It is highly effective when used correctly. Daily oral options and long-acting options exist internationally, but the available formulation and eligibility must be checked locally.
HIV testing is required before starting and during PrEP. A clinician also checks factors relevant to the selected medicine, including kidney function and hepatitis B for some oral regimens. Starting an inadequate prevention regimen during unrecognized HIV infection can promote resistance.
PrEP does not treat established HIV and is not a replacement for emergency PEP after a recent exposure. Event-based dosing is appropriate only for selected people and regimens under guidance; do not apply it to every medicine or type of sexual exposure. PrEP does not prevent pregnancy or all other sexually transmitted infections.
Condoms and safer injection practices
Use condoms correctly from the start to the end of sex. Water-based or silicone-based lubricant is compatible with latex condoms and can reduce friction and breakage. Oil-based products can damage latex. Do not use an internal and external condom together or two external condoms at once.
For injections, use new sterile needles, syringes and preparation equipment each time and do not share them. Sharing cookers, water or other equipment can also involve blood exposure. Harm-reduction services can provide safer equipment and support for substance-use treatment where available.
After an accidental blood exposure, seek prompt assessment rather than relying on disinfectant to eliminate the risk. PEP assessment may be needed, alongside evaluation for hepatitis B and C. Cleaning an injury is not a substitute for this assessment.
Pregnancy, birth and infant feeding
People living with HIV can have children without transmitting HIV when appropriate prevention and care are provided. ART before and during pregnancy, viral-load monitoring, delivery planning and preventive medicines for the baby substantially reduce transmission risk.
Infants need an age-appropriate testing schedule. Ordinary antibody testing alone is insufficient to diagnose young infants because maternal antibodies may still be present; virological testing is used. Continue the baby's follow-up even if an early result is reassuring.
Infant-feeding advice depends on national guidance, safe feeding alternatives and the individual situation. With sustained viral suppression, breastfeeding transmission risk is very low but not zero. Discuss feeding with the maternal and paediatric HIV team rather than assuming sexual U=U means breastfeeding carries no risk.
Mental health, stigma and care in Vietnam
An HIV diagnosis can bring fear, sadness or concerns about relationships. These reactions deserve support. Anxiety and depression are treatable, and addressing them can make sustained treatment easier. HIV is a medical condition, not a measure of a person's character.
Vietnam has HIV testing, ART and PrEP services, but local arrangements and medicine availability can change. Use a recognized HIV service for the relevant test and prevention or treatment pathway. For a possible exposure within 72 hours, prioritize urgent PEP assessment; for a reactive test, arrange confirmation and prompt linkage to care. Accurate testing and sustained treatment offer a clear path forward.
Frequently Asked Questions
Does hiv always need treatment?
No. The need for treatment depends on the diagnosis, severity, risks and individual context. A clinician or pharmacist can help determine the appropriate next step.
Can I diagnose or prescribe for myself from this article?
No. This is general information. Diagnosis, medicine doses and treatment decisions require individual assessment.
When should I seek urgent care?
Seek urgent care for trouble breathing, fainting, severe pain, confusion, new weakness, significant bleeding, a severe allergic reaction or rapidly worsening symptoms.
Where should I start in Vietnam?
Stable problems can often start with a general or relevant specialist clinic. Warning signs are more appropriate for a hospital emergency department.
What information should I bring to an appointment?
Bring a list of medicines and supplements, allergies, chronic conditions, symptom timing and any relevant test results or previous prescriptions.
Sources
Writer
Tan Nguyen
Medical writer for Vietnam Clinic. MD, Vietnam National University Ho Chi Minh City.
